Finance / Belgium
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Lucentis Made Available
October 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Thousands of Belgian patients could be saved from going blind after US firm Genentech's controversial drug Lucentis (ranibizumab), which treats wet age-related macular degeneration (AMD), was made available in the country, with the state picking up the lion's share of the cost.